We are live on ! Find out more
SSC

Spruce Street Capital Portfolio holdings

AUM $510M
This Fund
S&P 500
This Quarter Est. Return
+44.39%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$416M
AUM Growth
+$113M
Cap. Flow
+$9.08M
Cap. Flow %
2.18%
Top 10 Hldgs %
65.8%
Holding
34
New
7
Increased
12
Reduced
3
Closed
6

Top Buys

Rank Stock Value
1
ANRO icon
Alto Neuroscience
ANRO
+$20.4M
2
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$14.4M
3
CATX icon
Perspective Therapeutics
CATX
+$11.1M
4
CNTA
Centessa Pharmaceuticals
CNTA
+$10.5M
5
RLMD icon
Relmada Therapeutics
RLMD
+$10.3M

Top Sells

Rank Stock Value
1
CDTX
Cidara Therapeutics
CDTX
+$51.3M
2
ERAS icon
Erasca
ERAS
+$41M
3
EYPT icon
EyePoint Inc
EYPT
+$17.9M
4
OCUL icon
Ocular Therapeutix
OCUL
+$9.52M
5
PCVX icon
Vaxcyte
PCVX
+$8.4M

Sector Composition

Rank Sector Weight
1 Healthcare 98.78%
2 Financials 1.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RLMD icon
1
Relmada Therapeutics
RLMD
$512M
$43M 10.34%
6,262,114
+2,175,933
+53% +$10.3M
KNSA icon
2
Kiniksa Pharmaceuticals
KNSA
$5.99B
$36.6M 8.81%
761,063
+326,081
+75% +$14.4M
LBRX
3
LB Pharmaceuticals
LBRX
$1.54B
$33.6M 8.09%
1,376,159
+370,566
+37% +$8.55M
DNTH icon
4
Dianthus Therapeutics
DNTH
$6.49B
$31.3M 7.53%
373,274
+75,837
+25% +$4.39M
RLAY icon
5
Relay Therapeutics
RLAY
$4.35B
$29.7M 7.14%
2,984,125
– –
ANRO icon
6
Alto Neuroscience
ANRO
$1.25B
$29.1M 7%
1,325,210
+1,102,366
+495% +$20.4M
CNTA
7
DELISTED
Centessa Pharmaceuticals
CNTA
$19.5M 4.68%
489,849
+411,852
+528% +$10.5M
SVRA icon
8
Savara
SVRA
$1.11B
$18.5M 4.44%
3,383,175
+972,082
+40% +$5.41M
KALV
9
DELISTED
KalVista Pharmaceuticals
KALV
$18.1M 4.34%
897,681
+509,713
+131% +$8.22M
PCVX icon
10
Vaxcyte
PCVX
$8.64B
$14.3M 3.43%
245,709
-154,651
-39% -$8.4M
ELVN icon
11
Enliven Therapeutics
ELVN
$4.31B
$12.9M 3.1%
329,006
-117,078
-26% -$3.24M
SRZN icon
12
Surrozen
SRZN
$282M
$12.6M 3.03%
432,040
– –
ENTA icon
13
Enanta Pharmaceuticals
ENTA
$383M
$11.8M 2.83%
932,598
+542,911
+139% +$7.28M
ALKS icon
14
Alkermes
ALKS
$8.23B
$11.2M 2.7%
+317,992
New +$9.86M
CATX icon
15
Perspective Therapeutics
CATX
$365M
$11M 2.63%
+2,627,107
New +$11.1M
NERV icon
16
Minerva Neurosciences
NERV
$219M
$9.97M 2.4%
1,655,500
– –
IPSC icon
17
Century Therapeutics
IPSC
$348M
$9.17M 2.21%
4,059,054
+2,637,522
+186% +$5.55M
ALMS
18
Alumis Inc
ALMS
$3.23B
$8.65M 2.08%
+392,574
New +$9.81M
SABS icon
19
SAB Biotherapeutics
SABS
$337M
$8.42M 2.02%
2,198,502
– –
ERAS icon
20
Erasca
ERAS
$6.43B
$6.84M 1.64%
422,543
-3,467,089
-89% -$41M
IKT icon
21
Inhibikase Therapeutics
IKT
$378M
$6.02M 1.45%
3,581,603
– –
MAZE
22
Maze Therapeutics
MAZE
$1.51B
$5.97M 1.44%
+200,000
New +$8.83M
ANTX icon
23
AN2 Therapeutics
ANTX
$226M
$5.58M 1.34%
+1,661,073
New +$3.43M
LXEO icon
24
Lexeo Therapeutics
LXEO
$397M
$5.33M 1.28%
928,593
+753,593
+431% +$5.34M
HLXC
25
Helix Acquisition Corp III
HLXC
$243M
$5.08M 1.22%
+500,000
New +$5.12M
1
2

Similar funds

PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
MCA
Magnolia Capital Advisors Jackson, Mississippi $509M AUM 18.99% 1-Year Est. Return
AGC
Aspen Grove Capital Avon, Colorado $514M AUM 21.8% 1-Year Est. Return
PDIP
Palo Duro Investment Partners Chicago, Illinois $515M AUM 36.69% 1-Year Est. Return
LHC
Lodge Hill Capital New York $518M AUM 12.89% 1-Year Est. Return
MCCP
Mission Creek Capital Partners San Francisco, California $501M AUM 28.4% 1-Year Est. Return
AGP
Artia Global Partners Miami, Florida $499M AUM 186.05% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

Spruce Street Capital's Q1 2026 Portfolio in Review

As of Q1 2026, Spruce Street Capital held 34 positions worth $416M, up 37% from $303M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Spruce Street Capital's Q1 2026 filing shows 7 new, 12 increased, 3 reduced and 6 closed positions. Its largest new stake was Perspective Therapeutics: 2,627,107 shares worth $11M. The largest sale was Cidara Therapeutics, an estimated $51.3M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Financials.

  • Spruce Street Capital's largest Q1 2026 buy was Perspective Therapeutics: 2,627,107 shares worth $11M.
  • Spruce Street Capital added most to Alto Neuroscience in Q1 2026, an estimated $20.4M increase.
  • Spruce Street Capital's biggest Q1 2026 reduction was Erasca, cutting an estimated $41M.
  • Spruce Street Capital fully exited Cidara Therapeutics in Q1 2026, selling an estimated $51.3M.
  • Spruce Street Capital's ten largest holdings make up 66% of its $416M portfolio in Q1 2026.
  • Spruce Street Capital opened 7 new positions and closed 6 in Q1 2026.
  • Spruce Street Capital's portfolio value rose 37% quarter-over-quarter to $416M.

Based on Spruce Street Capital's 13F filing for Q1 2026, filed 14 May 2026.